Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CDNA vs NDRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDNA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

CDNA Overall Winner 6-Pillar Tally: CDNA 6 – 0 NDRA Matrix Metrics: CDNA 8 – 2 NDRA

As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDNA carries a Unified Composite Score of 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 0.0% operating margin) and revenue trajectory (+39.3% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDNA vs NDRA
CDNA NASDAQ Head-to-Head Winner
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap $4.1B
TTM Revenue $497M
Forward P/E 47.1x
Beta / 30D Vol 1.21β · 98% Vol
Unified Composite Score
24.5 / 100 STRONG SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 25.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.0 · SMA20: $77.09 · SMA50: $66.80
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32

6-Pillar Scorecard Institutional Category Breakdown (CDNA 6 – 0 NDRA)

Columns: Metric · CDNA · NDRA
1. Valuation Multiples CDNA
Forward P/E 47.1x N/M
Trailing P/E 32.9x N/M
PEG Ratio N/M N/M
EV / Revenue 7.8x N/M
2. Growth & Scale CDNA
Revenue Growth (YoY) +39.3% +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $497M N/A
Market Cap $4.1B $6.6M
3. Profitability & Quality CDNA
Gross Margin 71.0% N/A
Operating Margin 1.6% 0.0%
Net Profit Margin 25.9% 0.0%
Return on Equity (ROE) 33.0% -152.0%
4. Balance Sheet & Cash Flow CDNA
Cash Generation (TTM) $60M -$8.0M
Cash Flow Margin 12.0% N/A
Net Cash / Leverage $221M Net Cash $104,744 Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDNA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 56.8% (18th %ile) N/A (N/A)
Put/Call OI Skew 1.04x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CDNA
OpEx & R&D Intensity 69.4% of Rev ($345M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDNA (8) vs NDRA (2)
Institutional Metric CDNA NDRA Criterion Row Edge
Market Capitalization
Scale
$4.1B $6.6M Larger Scale CDNA
Trailing P/E Ratio
Valuation
32.9x N/M Lower Multiple CDNA
Forward P/E Ratio
Valuation
47.1x N/M Lower Multiple CDNA
Revenue Growth (YoY)
Growth
+39.3% +0.0% Higher Growth CDNA
Operating Margin (TTM)
Profitability
1.6% 0.0% Higher Margin CDNA
Net Profit Margin
Profitability
25.9% 0.0% Higher Margin CDNA
Return on Equity (ROE)
Capital Efficiency
33.0% -152.0% Higher ROE CDNA
52-Week Range Position
Momentum
77% ($15–$91) 37% ($3–$7) Stronger Trend CDNA
Beta / 30D Volatility
Risk Regime
1.21β · 98% Vol 0.71β · 48% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
24.5 / 100 (STRONG SELL) 44.7 / 100 (HOLD) Higher Composite NDRA
Trailing 12M Revenue (USD)
Operating Scale
$497M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$60M ($221M Net Cash) -$8.0M ($104,744 Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDNA +21.94 pp
CDNA: +15.19% · NDRA: -6.75%
3M Horizon CDNA +61.64 pp
CDNA: +59.64% · NDRA: -2.0%
6M Horizon CDNA +276.34 pp
CDNA: +258.04% · NDRA: -18.3%
1Y Horizon CDNA +397.24 pp
CDNA: +364.52% · NDRA: -32.72%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CDNA Revenue NDRA Revenue CDNA Op. Margin NDRA Op. Margin Margin Leader
FY2018 $80M $0M -20.3% -146080.5% CDNA
FY2019 $130M N/A -19.3% N/A CDNA
FY2020 $190M N/A -11.7% N/A CDNA
FY2021 $300M N/A -10.0% N/A CDNA
FY2022 $320M N/A -24.0% N/A CDNA
FY2023 $280M N/A -72.5% N/A CDNA
FY2024 $330M N/A 12.2% N/A CDNA
FY2025 $380M N/A -8.1% N/A CDNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDNA CONSOLIDATION
30d in phase · OBV NEUTRAL
Current IV 56.8%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDNA Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.1B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment 69.4% of Rev ($345M)
90D Engineering Disclosures 0 Published
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDNA vs NDRA Key Questions & Quantitative Answers

As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDNA carries a Unified Composite Score of 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 0.0% operating margin) and revenue trajectory (+39.3% vs. +0.0% YoY). Technical & Structure Timing Caution: CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDNA leads the Growth & Scale pillar: CDNA posts +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CDNA cumulative revenue shifted +375.0% while NDRA shifted N/A. In operating R&D and SG&A reinvestment, CDNA deploys 69.4% of Rev ($345M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.

CDNA screens cheaper on headline valuation multiples. CDNA trades at 47.1x Forward P/E, 32.9x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (12.0% FCF margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDNA (33.0% ROE) versus NDRA (-152.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CDNA carries 56.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 98% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.